SCIENCE
Involved in many disease pathologies, DUBs are attractive therapeutic targets
PLATFORM
World-leading DUB platform translating scientific advances into transformative therapies
PIPELINE
First-in-class small molecule DUB inhibitors developed in-house and with partners
USP30
Multiple in-house DUB inhibitor programs in the clinic or approaching clinical development
Mission Therapeutics
Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including Parkinson’s Disease (PD) and other neuro-degenerative conditions, heart and kidney diseases, fibrosis, and rare mitochondria diseases, by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).
Our lead candidates – MTX325 and MTX652 – aim to inhibit USP30, a DUB which can retard the essential cellular quality control process called mitophagy.
To hear our CEO discuss our technology, programs, recent progress and strategy, watch our Corporate Presentation.
